Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bimatoprost ophthalmic solution - Sun Pharma Advanced Research Company

Next Previous
Drug Profile

Bimatoprost ophthalmic solution - Sun Pharma Advanced Research Company

Alternative Names: SDP-133

Latest Information Update: 28 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sun Pharma Advanced Research Company
  • Class Amides; Antiglaucomas; Eye disorder therapies; Lipids; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2alpha receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 28 May 2022 No recent reports of development identified for clinical-Phase-Unknown development in Ocular-hypertension in USA (Ophthalmic, Liquid)
  • 28 May 2022 No recent reports of development identified for clinical-Phase-Unknown development in Open-angle-glaucoma in USA (Ophthalmic, Liquid)
  • 08 Jul 2019 Sun Pharma withdraws a phase III trial in Ocular hypertension and Open-angle glaucoma, due to sponsor's withdrawal decision (Ophthalmic) (NCT03927443)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top